REVERSIBLE TRABECULAR BONE DENSITY LOSS FOLLOWING INDUCED HYPO‐OESTROGENISM WITH THE GnRH ANALOGUE BUSERELIN IN PREMENOPAUSAL WOMEN

W H Matta, W Matta, Robert W. Shaw, R W Shaw, R Hesp, R Evans, Rachael A Evans
Clinical endocrinology · 1988 · vol. 29(1) , pp. 45–51 · doi:10.1111/j.1365-2265.1988.tb00248.x · PMID:3150319 · W2089856942
article OA: closed CC0 ⤵ 40 in-corpus citations
View on OpenAlex View on PubMed View at publisher

Abstract

Thirteen premenopausal women who each received 400 micrograms three times daily of intranasal buserelin for 6 months as treatment for endometriosis participated in this study. Cortical bone mineral content (BMC) in the mid-shaft of the right femur measured by dual photon densitometry, and trabecular bone density (TBD) in the lumbar vertebrae (L2-4) measured by quantitative computed tomography, were evaluated prior to, at the end of 6 months' buserelin treatment and after 6 months off treatment. Significant hypo-oestrogenism (P less than 0.001) was sustained during the period on treatment. The significant reduction in the mean lumbar vertebral TBD of 5.9% (P less than 0.02) observed at the end of treatment with buserelin was regained within 6 months following resumption of ovarian activity. There was a marginally significant (P = 0.07) reduction of only 0.9% in the mean femoral cortical BMC at the end of treatment. Six months after the end of treatment cortical BMC values were not significantly different from the pretreatment values. There was no significant correlation between the degree of hypo-oestrogenism and the corresponding change in vertebral TBD, (r = 0.20; P less than 0.10).

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Bone and Bones Buserelin Endometriosis Adult Bone and Bones Buserelin Buserelin Endometriosis Endometriosis Endometriosis Female Femur Femur Humans Lumbar Vertebrae Lumbar Vertebrae Menopause Minerals Minerals Ovary

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (21)

Cited by (40)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:09:20.810540+00:00
License: CC0 · commercial use OK